☆ 4.6 Article

Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany

VALUE IN HEALTH (2023)

Related references

Note: Only part of the references are listed.

Article Economics

Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma

Olivia M. Dong et al.

Summary: This study compared the cost-effectiveness of comprehensive genomic profiling and targeted gene panel testing in patients with metastatic lung adenocarcinoma. The results showed that tumor profiling can improve quality-adjusted survival but is not cost-effective.

VALUE IN HEALTH (2022)

Add to Collection

Article Health Care Sciences & Services

Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews

Chantelle Garritty et al.

Summary: The study aims to develop guidance to support the conduct of rapid reviews, with 26 recommendations presented based on survey results. These recommendations will help synthesize evidence for urgent health issues, but the guidance will need to be updated as new evaluations for some RR methods are conducted due to the current lack of available evidence.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness

Peter Murphy et al.

Summary: This study investigates the impact of heterogeneity in response rates across histologies on the cost-effectiveness of histology-independent technologies (HITs). Using a Bayesian hierarchical model, considerable variation in response rates was found, with lower predicted response probabilities for new histologies compared to naively pooled probabilities. Accounting for heterogeneity led to a wide range of cost-effectiveness probabilities for different approval decisions, highlighting the importance of considering heterogeneity in reimbursement of HITs.

MEDICAL DECISION MAKING (2021)

Add to Collection

Article Oncology

Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

Denis Horgan et al.

Summary: The trend towards personalized cancer treatment is supported by increasing data, but implementation is hindered by low acceptance in health systems. Harmonizing cancer treatment pathways in Europe is crucial for more efficient services.

CANCERS (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, Research & Experimental

Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials

Liyun Jiang et al.

Summary: The article discusses the application of Bayesian hierarchical model in tissue-agnostic trials and proposes the OBHM and COBHM methods to address inherent issues. The COBHM approach clusters tumor types to achieve more accurate information borrowing, balancing power and type I error effectively. Simulation study shows that COBHM outperforms existing methods in operating characteristics.

CONTEMPORARY CLINICAL TRIALS (2021)

Add to Collection

Article Economics

PCN198 Statistical Methods for Pantumor Analysis: Models to Account for Tumor-Level Heterogeneity

A. Swaminathan et al.

VALUE IN HEALTH (2021)

Add to Collection

Review Oncology

Drug Development in Tissue-Agnostic Indications

Pauline du Rusquec et al.

Summary: The primary goal of oncology interventions is to improve overall survival and quality of life. Randomized controlled trials are the gold standard for demonstrating treatment efficacy. Advances in cancer biology have led to targeted therapies designed to modulate molecular pathways in cancer cells, challenging traditional drug development paradigms.

CANCERS (2021)

Add to Collection

Article Economics

Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies

Jennifer G. Gaultney et al.

Summary: The advent of precision oncology is challenging the conventional standards for evaluating and approving technologies, especially in the assessment of histology-independent therapies. This has led to a variety of challenges, including uncertainty in benefits, trial design, and the inability to identify the benefits of standard care in daily practice. Proposed solutions aim to address these challenges and ensure a consistent approach to evaluating histology-independent therapies.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)

Add to Collection

Article Oncology

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

C. B. Westphalen et al.

Summary: NTRK gene fusions are rare oncogenic drivers in solid tumors, with a prevalence of 0.30% across various cancers and notable variations based on age, cancer type, and histology. Combining large datasets helps in better understanding the characteristics of these rare molecular subgroups of cancer, revealing unique genomic patterns and fusion partners. The presence of NTRK gene fusions did not correlate with other clinically actionable biomarkers, showing distinct genetic features in NTRK fusion-positive tumors.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

An overview of precision oncology basket and umbrella trials for clinicians

Jay J. H. Park et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Oncology

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Review Pathology

Site-agnostic biomarker-guided oncology drug development

Jan Trost Jorgensen

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2020)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

Tumour-agnostic therapies

Ann-Marie Looney et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Sophie Cooper et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Letter Medicine, General & Internal

Histology independent cancer drugs: the drug makers' responsibility

Daniel A. Ollendorf

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Economics

PCN262 Understanding the Challenges in the Evaluation of Tumour-Agnostic Therapies: Barriers Posed By the Current Trial Designs and Future Trends

N. Delimpaltadakis et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

RE1 Financing and Reimbursement for Personalised Medicine - Are WE There YET?

R. Koleva-Kolarova et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

PCN233 Communicating VALUE to Payers for Tumor-Agnostic Therapies

M. Hunt et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

PPM2 Decision Modelling Approaches for Histology-Independent Cancer Technologies

R. Hodgson et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

PPM12 DATA Collection and Heterogeneity: Implications for Histology-Independent Decision Making

P. Murphy et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

HTA1 Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets

M. Rodes Sanchez et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Economics

PCN241 Complex Innovative Design Trials: Too Complex for Market Access?

P. Hartikainen et al.

VALUE IN HEALTH (2020)

Add to Collection

Article Health Policy & Services

Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation

Sabine Vogler et al.

COST EFFECTIVENESS AND RESOURCE ALLOCATION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials

Adam C. Palmer et al.

CELL SYSTEMS (2020)

Add to Collection

Meeting Abstract Economics

CHALLENGES AND AN APPROACH TO PERFORMING COST-EFFECTIVENESS ANALYSES BASED ON SINGLE ARM BASKET TRIALS FOR PAN-TUMOR INDICATIONS

P. Orfanos et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Economics

PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS

C. Boehmer et al.

VALUE IN HEALTH (2019)

Add to Collection

Meeting Abstract Economics

TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?

B. Khogeer et al.

VALUE IN HEALTH (2018)

Add to Collection

Review Oncology

Precision medicine becomes reality-tumor type-agnostic therapy

Li Yan et al.

CANCER COMMUNICATIONS (2018)

Add to Collection

Review Oncology

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

Matthew D. Galsky et al.

INVESTIGATIONAL NEW DRUGS (2010)

Add to Collection

Article Social Sciences, Interdisciplinary

Simultaneous and Sequential Qualitative Mixed Method Designs

Janice M. Morse

QUALITATIVE INQUIRY (2010)

Add to Collection

Article Health Care Sciences & Services

Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups

Allison Tong et al.

INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.